Basement membrane-based glucose sensor coatings enhance continuous glucose monitoring in vivo

Journal of Diabetes Science and Technology

Volumn 9, Issue 5, 2015, Pages 957-965

  Klueh, Ulrike ^a   Qiao, Yi ^a   Czajkowski, Caroline ^a   Ludzinska, Izabela ^a   Antar, Omar ^a   Kreutzer, Donald L ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Basement membrane; Biocompatibility; Continuous glucose monitoring; Extracellular matrices; Glucose sensor coatings; Implantable glucose sensor; Trevigen

Indexed keywords

GENTAMICIN; POLITEF; GLUCOSE BLOOD LEVEL; HYDROGEL;

ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BLOOD GLUCOSE MONITORING; CELL INFILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HYDROGEL; IMPLANTATION; MATHEMATICAL MODEL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERFORMANCE; TISSUE REACTION; ANALYSIS; ANIMAL; DEVICES; GENETIC PROCEDURES; INSULIN INFUSION; PROCEDURES;

ANIMALS; BIOSENSING TECHNIQUES; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; HYDROGELS; INSULIN INFUSION SYSTEMS; MICE;

EID: 84969415795     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815598776     Document Type: Article

References (37)

1. Gifford R. Continuous glucose monitoring: 40 years, what we've learned and what's next. Chemphyschem. 2013; 14(10): 2032-2044.
2. Buhling KJ, Kurzidim B, Wolf C, et al. Introductory experience with the continuous glucose monitoring system (CGMS; Medtronic Minimed) in detecting hyperglycemia by comparing the self-monitoring of blood glucose (SMBG) in non-pregnant women and in pregnant women with impaired glucose tolerance and gestational diabetes. Exp Clin Endocrinol Diabetes. 2004; 112(10):556-560.
3. Djakoure-Platonoff C, Radermercker R, Reach G, Slama G, Selam JI. Accuracy of the continuous glucose monitoring system in inpatient and outpatient conditions. Diabetes Metab. 2003; 29(2 pt 1): 159-162.
4. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology-results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003; 5(5):769-779.
5. Kapitza C, Lodwig V, Obermaier K, et al. Continuous glucose monitoring: reliable measurements for up to 4 days with the SCGM1 system. Diabetes Technol Ther. 2003; 5(4):609-614.
6. Maran A, Crepaldi C, Tiengo A, et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care. 2002; 25(2):347-352.
7. Tansey MJ, Beck RW, Buckingham BA, et al. Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes Technol Ther. 2005; 7(1):109-114.
8. Kudo H, Sawada T, Kazawa E, Yoshida H, Iwasaki Y, Mitsubayashi K. A flexible and wearable glucose sensor based on functional polymers with soft-MEMS techniques. Biosens Bioelectron. 2006; 22(4):558-562.
9. Kvist PH, Iburg T, Aalbaek B, et al. Biocompatibility of an enzyme-based, electrochemical glucose sensor for short-term implantation in the subcutis. Diabetes Technol Ther. 2006; 8(5):546-559.
10. Kvist PH, Iburg T, Bielecki M, et al. Biocompatibility of electrochemical glucose sensors implanted in the subcutis of pigs. Diabetes Technol Ther. 2006; 8(4):463-475.
11. Mang A, Pill J, Gretz N, et al. Biocompatibility of an electrochemical sensor for continuous glucose monitoring in subcutaneous tissue. Diabetes Technol Ther. 2005; 7(1):163-173.
12. Nishida K, Sakakida M, Ichinose K, et al. Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate. Med Prog Technol. 1995; 21(2):91-103.
13. Poitout V, Moatti-Sirat D, Reach G. Development of a glucose sensor for glucose monitoring in man: the disposable implant concept. Clin Mater. 1994; 15(4):241-246.
14. Ju YM, Yu B, West L, Moussy Y, Moussy F. A novel porous collagen scaffold around an implantable biosensor for improving biocompatibility. II. Long-term in vitro/in vivo sensitivity characteristics of sensors with NDGA- or GA-crosslinked collagen scaffolds. J Biomed Mater Res A. 2010; 92(2):650-658.
15. Klueh U, Frailey JT, Qiao Y, Antar O, Kreutzer DL. Cell based metabolic barriers to glucose diffusion: macrophages and continuous glucose monitoring. Biomaterials. 2014; 35(10):3145-3153.
16. Ju YM, Yu B, Koob TJ, Moussy Y, Moussy F. A novel porous collagen scaffold around an implantable biosensor for improving biocompatibility. I. In vitro/in vivo stability of the scaffold and in vitro sensitivity of the glucose sensor with scaffold. J Biomed Mater Res A. 2008; 87(1):136-146.
17. Klueh U, Qiao Y, Frailey JT, Kreutzer DL. Impact of macrophage deficiency and depletion on continuous glucose monitoring in vivo. Biomaterials. 2014; 35(6):1789-1796.
18. Orenstein SB, Saberski ER, Kreutzer DL, Novitsky YW. Comparative analysis of histopathologic effects of synthetic meshes based on material, weight, and pore size in mice. J Surg Res. 2012; 176:423-429.
19. Hall H, Baechi T, Hubbell JA. Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro. Microvasc Res. 2001; 62(3):315-326.
20. Wagner WR, Hubbell JA. Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen in heparinized blood. J Lab Clin Med. 1990; 116(5):636-650.
21. Sakiyama SE, Schense JC, Hubbell JA. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering. Faseb J. 1999; 13(15):2214-2224.
22. Ye Q, Zund G, Benedikt P, et al. Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2000; 17(5):587-591.
23. Schense JC, Bloch J, Aebischer P, Hubbell JA. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nat Biotechnol. 2000; 18(4): 415-419.
24. Herbert CB, Nagaswami C, Bittner GD, Hubbell JA, Weisel JW. Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels. J Biomed Mater Res. 1998; 40(4):551-559.
25. Herbert CB, Bittner GD, Hubbell JA. Effects of fibinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels. J Comp Neurol. 1996; 365(3):380-391.
26. Sakiyama-Elbert SE, Hubbell JA. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J Control Release. 2000; 69(1):149-158.
27. Schense JC, Hubbell JA. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem. 1999; 10(1):75-81.
28. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release. 2001; 72(1-3):101-113.
29. Xue L, Greisler HP. Angiogenic effect of fibroblast growth factor-1 and vascular endothelial growth factor and their synergism in a novel in vitro quantitative fibrin-based 3-dimensional angiogenesis system. Surgery. 2002; 132(2):259-267.
30. Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost. 2000; 83(5):736-741.
31. Pandit AS, Wilson DJ, Feldman DS. Fibrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-1). J Biomater Appl. 2000; 14(3):229-242.
32. Quirinia A, Viidik A. The effect of recombinant basic fibro-blast growth factor (bFGF) in fibrin adhesive vehicle on the healing of ischaemic and normal incisional skin wounds. Scand J Plast Reconstr Surg Hand Surg. 1998; 32(1):9-18.
33. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 2000; 96(12):3772-3778.
34. Albini A. Tumor and endothelial cell. invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998; 4(3):230-241.
35. Benelli R, Albini A. In vitro models of angiogenesis: the use of Matrigel. Int J Biol Markers. 1999; 14(4):243-246.
36. Yamamura K, Kibbey MC, Jun SH, Kleinman HK. Effect of Matrigel and laminin peptide YIGSR on tumor growth and metastasis. Semin Cancer Biol. 1993; 4(4):259-265.
37. Klueh U, Liu Z, Cho B, et al. Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol Ther. 2006; 8(3):402-412.